Brodalumab

證據等級: L5

預測適應症: 10 個

Brodalumab: From [Original Indication Not on File] to Strongyloidiasis (Flagged as a Safety Signal, Not a Confirmed Opportunity)

One-Sentence Summary

Brodalumab is an anti-IL-17RA monoclonal antibody; the Evidence Pack contains no populated original_indications field, so its originally approved use cannot be sourced from this dataset. The TxGNN model's top-ranked "new indication," Strongyloidiasis, is supported by 0 clinical trials and 0 publications, and the model's own repurposing rationale states this association is mechanistically inverted — IL-17 signaling is protective against intestinal helminth infection, so blocking IL-17RA would be expected to worsen, not treat, strongyloidiasis. This candidate should be read as a possible pharmacovigilance signal, not a repurposing lead.

Quick Overview

Item	Content
Original Indication	Not documented in this Evidence Pack (`original_indications` empty, `original_moa` = Data Gap; drug is not marketed in Finland)
Predicted New Indication	Strongyloidiasis
TxGNN Prediction Score	99.84%
Evidence Level	L5 (model prediction only, no supporting studies)
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for brodalumab is not available in this Evidence Pack (original_moa = Data Gap). Based on information embedded in the repurposing rationale fields, brodalumab is described as an anti-IL-17RA monoclonal antibody, i.e., a full blocker of IL-17 receptor signaling — the same class as secukinumab and ixekizumab, which target IL-17-driven inflammatory diseases such as plaque psoriasis and psoriatic arthritis.

For the top-ranked prediction, strongyloidiasis, the mechanistic direction runs the opposite way from a therapeutic hypothesis. IL-17 is a key host-defense cytokine against extracellular parasites, including Strongyloides stercoralis. Blocking IL-17RA would be expected to impair anti-helminth immunity and could plausibly increase the risk of infection or hyperinfection syndrome in susceptible patients — a known class-level concern for IL-17 inhibitors — rather than provide a treatment benefit. The Evidence Pack's own rationale explicitly flags this as "likely a reverse or confounded association in the TxGNN knowledge graph" rather than a genuine treatment signal, and no clinical trials, ICTRP records, or literature exist to counter that interpretation.

The remaining candidates in the top-10 list follow a similar pattern: most are rare ophthalmic/optic-nerve conditions (e.g., von Hippel anomaly, optic perineuritis, episcleritis subtypes) with no clinical or literature evidence (L5), and several carry the same directional caution — IL-17 inhibitors as a class have documented case reports of triggering or worsening demyelinating/optic neuritis-type events, making those associations candidate safety signals rather than repurposing opportunities. Rank 2, "eye disease," has one linked trial and one publication, but the trial is a general immune-mediated skin disease registry (SKINERGY) unrelated to ophthalmology, and the literature is a general IL-17-blockade review — neither constitutes disease-specific evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Brodalumab has 0 registered authorizations and is not currently marketed in Finland (total_licenses: 0, licenses: []). No product-level authorization data is available.

Safety Considerations

Please refer to the package insert for safety information.

Note: this Evidence Pack flags TFDA label warnings/contraindications as a Blocking data gap (DG001) — safety pre-assessment (S1) cannot proceed until the package insert is retrieved and parsed. Drug interaction lookup also returned no results (query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (strongyloidiasis) has no supporting clinical or literature evidence (L5) and its own mechanistic rationale points in the opposite direction — toward a safety risk rather than a therapeutic benefit. No candidate in the top 10 reaches an evidence level beyond L4, and the one candidate with any linked evidence ("eye disease," L4) is not disease-specific and appears to reflect a database mapping mismatch.

To proceed, the following is needed:

Retrieve and parse the TFDA/Fimea package insert to close the Blocking safety data gap (DG001) before any S1 assessment
Obtain verified mechanism-of-action data from DrugBank (DG002) to properly evaluate mechanistic plausibility
If "eye disease" is pursued further, first narrow it to a specific IL-17-linked ocular diagnosis (e.g., uveitis) and re-query trials/literature against that specific term
Route the strongyloidiasis association to pharmacovigilance/signal-detection review rather than the repurposing pipeline, given its mechanistically inverted direction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.